Bioscreen Instruments Launches Distribution of PBIO’s PCT Instruments and Consumables into Third Largest Pharmaceutical and Largest Global Supply Sectors of Generic Medicines Worldwide; Expects Strong Sales of PBIO’s PCT Barocycler System in Months and Years to Come

SOUTH EATON, MA / ACCESSWIRE / October 18, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and testing services to the global pharmaceuticals, nutraceuticals, cosmeceuticals, agrochemical, food/beverage, and other industries, today announced its partnership with Bioscreen Instruments PVT LTD (“Bioscreen”), launching an exclusive instrument and consumables distribution agreement for India. The Indian pharmaceutical industry is 13^th largest by value and third largest by volume in the world, is the largest global supplier of generic medicines, and is ranked third in the world in terms of dollar value of drugs and medicines exports (IndianPharmaIndustry). Bioscreen is widely respected as a leading supplier of highly advanced lab automation, instruments, and consumables to India’s massive and growing life sciences industry.

John Hollister, PBIO Director of Sales and Marketing commented: “We are very excited about entering the Indian market, for its own opportunity scale and for its strongly established worldwide presence in biotech and pharmaceuticals. Bioscreen has, over almost two decades, demonstrated their commitment to leadership in distribution and support for very sophisticated equipment, which matches perfectly with our Pressure Cycling Technology (PCT) line of Barocycler™ instruments, consumables, and peripherals. We are very impressed with the level of industry understanding, skill, and commitment demonstrated by their team. We look forward to an incredibly productive and prestige-building relationship.”

Bioscreen’s Director of Sales and Marketing, S. Prabhakar offered: “We see PBIO’s well-established Barocycler PCT line as a natural fit in our array of lab offerings for our biotech, contract manufacturing, university and government research, and pharmaceutical client partners. Many of our customers are focused on research or manufacturing processes involving biological samples, where this revolutionary instrument tool offers tremendous advantages in scientific results and insights over other current methods of sample preparation. We have already begun sharing this important product line addition with selected leading customers and are receiving a wonderful reception. We look forward to selling and installing a great number of Barocycler instruments and consumables in the months and years to come.”

Richard T. Schumacher, President and CEO of PBIO, expanded: “Our team has been focusing the majority of our efforts on the launch of our revolutionary UltraShear™ nanoemulsions processing platform, which we expect to be pivotal to ramping revenue in the fourth quarter of 2023, and beyond. However, our commitment to supporting the PCT Platform, which has for years been the backbone of our Company, remains unwavering. We are honored and humbled to have partnered with such a renowned and leading life sciences distribution company in India. With access to one of the world’s largest and fastest growing life sciences markets, and with established access to many thousands of companies making up this market, we believe PCT instrument and consumables sales in 2024 will be a strong contributor to PBIO’s growth trajectory as well!”

Patent Protects PBIO’s Exclusive Rights to Commercialize UltraShear Platform in Canada, Leveraging Unique, Best-in-Class Nanoemulsions Processing Performance with Full Commercial Scalability

SOUTH EASTON, MA / ACCESSWIRE / October 10, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and testing services to the global pharmaceuticals, nutraceuticals, cosmeceuticals, food/beverage, agrochemical, and other industries, today announced the award of the first Canadian patent for its revolutionary UltraShear^TM Technology (UltraShear^TM or UST^TM) platform. Entitled “System for High Pressure, High Shear Processing of Fluids”, this new patent (Canadian No. 2981058) brings the Company’s intellectual property (“IP”) estate for the UltraShear Technology platform to eight issued patents and the Company’s total IP estate to 43 issued patents with another 21 pending applications.

The UltraShear platform was created to revolutionize the processing of normally immiscible mixtures of oil-soluble and water-soluble components into long-term stable, effectively water-soluble, easily absorbable and highly bioavailable nanoemulsions. Emulsions of oil and water components typically require the addition of chemicals called emulsifiers (e.g., surfactants) in order to produce stable macro- or micro-emulsions. Emulsions are critically important for thousands of products in everyday use, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, skincare, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Scientific data now corroborate that greatly accelerated and improved absorption, higher bioavailability, greater stability, lower surfactant levels, and other advantages (such as more efficient and reliable dosing) are achieved with high quality nanoemulsions.

Based on peer-reviewed scientific research, customer feedback, and multiple consumer focus group studies, PBIO has established the differentiation of its patented UltraShear Technology platform as the best-in-class nanoemulsion performance and delivery system worldwide. The Company believes the evidence is compelling that its UltraShear Technology platform delivers unequalled values for the diverse global industries ready to benefit from world-class nanoemulsions performance and production scalability, including nutraceuticals, pharmaceuticals, cosmeceuticals, agrochemicals, and even in food and beverages.

Dr. Edmund Y. Ting, Sr. Vice President of Engineering of PBI and the inventor on this patent, said: “Nanoemulsions have long been shown to exhibit improved absorption, higher bioavailability, and greater stability, while often requiring lower levels of emulsifiers than macro/micro emulsion products. Because of these significant advantages, nanoemulsions are currently the focus of numerous research efforts worldwide. However, cost-effective scale-up of high quality nanoemulsion processing at a commercial level has long remained to be quite challenging. Importantly, we believe that PBI’s innovative, patented, and now Canadian patent-protected UltraShear platform will provide the pivotal key to commercial success for nanoemulsion products.”

Mr. John B. Hollister, Director of Marketing and Sales, said: “We recently set up an UltraShear Nano-CBD processing site in Massachusetts. We are closing in on customer orders for nearly one-million dollars of UltraShear Nano-CBD topical spray to be supplied over the next year, product processing has started, and shipment of finished product ready for customer white-labeling began last week. UltraShear is no longer a research tool; it has become a revenue-generating machine.”

Mr. Kenneth F. Micciche, Director of Business Development, added: “A number of our Canadian colleagues were ecstatic when told of the award of our first Canadian UltraShear patent. This initial patent opens up many possibilities in Canada, from setting up toll-processing sites, to future lease/license arrangements, to joint ventures. Regardless of the path we choose, we believe that patent protection in Canada will quickly translate into additional escalating revenues for the Company.”

PBIO Acknowledges Rapidly Emerging Demand Potential for UltraShear Nanoemulsions for Transformation of Diverse Major Markets, with Recently Announced Readiness and Scaling Plans

SOUTH EASTON, MA / ACCCESSWIRE / September 22, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and testing services to the global nutraceuticals, cosmeceuticals, food/beverage, biotherapeutics, and other industries, and the Veterans Service Team (“VST”) (www.vst.org), a self-funded, 501(c)3 non-profit company dedicated to the support and wellness of active duty and former members of all branches of the US Military and US Coast Guard, today announced that VST has increased its existing purchase order with PBIO by 10-fold (from 500 to 5,000 bottles), effective immediately.

PBIO’s Ultra Shear Technology^TM (UltraShear^TM or UST^TM) platform allows oil-soluble active molecules like CBD to be prepared into nanoemulsions of vanishingly tiny oil droplets in water that ensure rapid absorption and unparalleled bioavailability of the CBD (or other active ingredients) into the water-based biochemistry of human bodies. The PBIO-VST partnership offers VST membership exclusive access to custom-designed, hemp-derived, UltraShear-processed nanoemulsions of CBD oil in water (“Nano-CBD”), providing unparalleled speed of action and reliable dosage delivery. VST is initially launching their uniquely differentiated UltraShear Nano-CBD Topical Spray, with plans for its sister product, UltraShear Nano-CBD Oral Spray, to quickly follow.

In a June 2023 press release announcing the new, five-year partnership between VST and PBIO, Mr. Howard Zall, COO of VST, explained that a leading-quality CBD product with world class speed and completeness of dose delivery and effectiveness had been the most important new offering that VST was targeting in 2023, to help address and manage a diversity of critical needs for their members. Mr. Zall stated they had determined that PBIO’s UltraShear Technology was the world’s leading platform for developing highly effective nanoemulsions of CBD in either a topical or oral spray. They were (and are) excited to partner with PBIO, to soon introduce to their membership the first product to emerge from this collaboration: a revolutionary, all-natural, preservative-free, highly potent, UltraShear nanoemulsified CBD topical spray.

Mr. John B. Hollister, Director of Marketing and Sales, commented: “Yesterday we announced the successful expansion of internal capabilities to ensure the fulfillment of existing orders, starting in early October. Today we are announcing a 10-fold increase in the number of bottles of one of these existing orders. Although this request is a significant increase, it is important to note that our VST partner has advised us that this may be the “tip of the iceberg”, and that PBIO needs to be ready to respond to such large orders in the near future, both often and quickly.”

Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: “As stated in our June announcement, VST believes their membership will exceed two million of the nearly 18 million active-duty personnel and veterans within five years. PBIO and VST estimate that PBIO’s revenue from this relationship will significantly grow year-over-year, from initial annual revenue of about $1.5M to as much as $15M in the fifth year of the agreement. These projections are for Nano-CBD products sales only (both topical and oral), which the companies believe will be generated from sales of up to 50,000 spray bottles in Year 1 to approximately 500,000 spray bottles in Year 5. PBIO investors and VST members can expect to hear much more about additional UltraShear processed products developed and offered through VST in the months ahead.”

About Veterans Service Team (VST)

The VST mission is to serve the roughly 18 million current members and veterans of the US Armed Services and Coast Guard with education, support services, and a potent collection of diverse, carefully selected health and wellness products. VST is in the early stages of building membership, through which they expect to increase VST to over 2 million members in the next five years. VST’s founder, Captain George Ackerson, is an exceptional individual with a strong, diverse background. As a seasoned business professional and former Military Officer, he brings a wealth of experience to the table. Notably, Captain Ackerson served in Vietnam as a Special Ops Scout Helicopter Pilot, demonstrating his bravery and commitment to service. Captain Ackerson’s passion lies in supporting fellow veterans by leveraging his extensive knowledge and expertise. With a deep understanding of health and wellness, he strives to make a meaningful impact and empower others through innovative approaches.

Further Innovations Announced, with All Systems Go for Fulfilling Current and Future Orders; UltraShear is No Longer Just the Name of a Patented, Revolutionary, One-of-a Kind Nanoemulsification Process, It is Now a Revenue-Generating Machine.

SOUTH EASTON, MA / ACCESSWIRE / September 21, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide nutraceuticals, cosmeceuticals, food and beverage, biotherapeutics, and other industries, today announced that the Company’s initial expansion of its launch-phase manufacturing capacity has been completed, that backorders of reagents and supplies needed for Nano-CBD processing by the Company’s patented UltraShear^TM Technology platform (UltraShear^TM or UST^TM) have been received, and that a review of the Company’s Quality Systems has been completed. The Company will begin fulfilling the orders it has received and announced over the past six weeks, with an expectation that initial shipments of product will begin the week of October 2^nd and that new orders will continue to grow throughout the Company’s fourth quarter, and beyond.

The UltraShear process is used to create a Nano-CBD Topical Spray, with uniquely uniform and ultra-low nano-droplet sizes of hemp-derived CBD oil in water, creating a best-in-class, super-fast acting, highly bioavailable, all natural, preservative-free, and highly potent (40 mg/ml) CBD product. CBD has been heavily popularized by researchers and consumers alike for addressing pain, stress, anxiety, sleep disorders and more. PBIO has also recently disclosed the completion of an important preclinical study performed by leading academics, as well as consumer focus group testing in commercial settings, all providing compelling supporting evidence for its revolutionary improvements over conventional CBD edibles and its “best-in-class” nanoemulsion performance. The Company anticipates imminent publication in a scientific peer-reviewed journal of research performed by a leading global cannabis academic research team, highlighting vastly superior absorption and bioavailability achieved by PBIO’s UltraShear Nano-CBD.

Recently, PBIO has announced the achievement of a number of milestones in its Nano-CBD project, including:

• Second progress report on UltraShear Nano-CBD launch (“Drive to 420”) -five new orders received (Aug 30)
• Strongly accelerating UltraShear Nano-CBD orders. First five purchase orders received. (Aug 9)
• Evaluation of the UltraShear process for shelf-life extension coatings on fresh produce. (July 25)
• Nano-CBD commercial rollout program enters rapid expansion Phase 2. (July 17)
• Nano-CBD topical spray distribution agreement with leading CA company Crème de Canna. (July 10)
• Key academic publication further validates PBIO’s UltraShear platform’s impact in clean-label foods. (July 6)
• Partnership with Somalab International for development of UltraShear-enabled health products. (July 5)
• PBIO partners with Veterans Service Team to offer exclusive access for VST members to Nano-CBD. (June 13)
• Commercial availability of Best-in-Class Nano-CBD topical spray with lightning-fast action announced. (May 22)

Mr. John B. Hollister, Director of Marketing and Sales, commented, “We have 10 purchase orders in hand, with an estimated value of up to half a million dollars. We expect to close on an additional 15 orders before the end of 2023, and to have a minimum of 50 orders within a year. The PBIO team has worked hard to expand our capabilities and to acquire the necessary materials and equipment to help ensure that we can begin to fulfill the orders in hand by early October, as well as anticipated new orders as they arrive. We have succeeded in both: our manufacturing capabilities are now ready for prime time and the fulfillment of the initial hundreds of thousands of dollars of orders has begun.”

Mr. Hollister continued: “While we have spent recent weeks focused on closing initial orders, we have also been completing enormous amounts of preparatory work in getting PBIO ready to fulfill current and future production demands and have introduced new innovations in the process. We are particularly pleased to have sourced an innovative spray dispensing bottle format that incorporates a laboratory standard 0.2 micron filter in the air return pathway (air drawn in to replace air expelled during spraying). Starting with our all-natural, preservative-free product design and the effective sterility achieved during UltraShear processing, this innovative filtered spray bottle design helps to protect and maintain product sterility and stability during routine use and complements our prioritization of a green/clean-label consumer-responsive design.”

Mr. Richard T. Schumacher, President and CEO, said: “PBIO has reached the inflection point that we have discussed over recent months. We are not just launching into the fulfilment of the hundreds of thousands of dollars in orders that we have in-hand, but we are also now prepared and ready for fulfillment of the additional orders anticipated throughout the fourth quarter and beyond. While it has been a long and winding road for our team and our shareholders, the good news is that the sun is shining bright on the super-highway opening up ahead of us. UltraShear is no longer just the name of a patented, revolutionary, one-of-a kind nanoemulsification process, it is now a revenue-generating machine!”